Literature DB >> 8273557

Effect of ETH615, an inhibitor of leukotriene synthesis and IL-8 gene expression, on murine dermatoses.

I Ahnfelt-Rønne1, H Aaes, T Skak-Nielsen.   

Abstract

ETH615 (4-[2-quinolylmethoxy]-N-[3-fluorobenzyl]-phenylaminometh yl-4-benzoic acid) is a potent inhibitor of leukotriene biosynthesis in A23187-stimulated leukocytes, and of IL-8 gene expression in LPS-stimulated PBMC. It shows anti-inflammatory activity in a canine model of dermal inflammation. A topical formulation is present in phase II clinical trials. In the present study the effect of ETH615 on oxazolone-induced acute inflammation and phorbol ester-induced chronic inflammation in the mouse ear was investigated. Betamethasone (0.04 mg/ear) and ETH615 (1-1.5 mg/ear) significantly inhibited both the oedema formation and the PMN infiltration. The cream and ointment formulations of ETH615 developed for clinical studies were equally active. ETH615 is thus an anti-inflammatory agent in these murine models of dermatosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8273557     DOI: 10.1007/bf01972755

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  4 in total

1.  Inhibition of leukotriene biosynthesis and polymorphonuclear leukocyte functions by orally active quinolylmethoxyphenylamines.

Authors:  D Kirstein; M K Thomsen; I Ahnfelt-Rønne
Journal:  Pharmacol Toxicol       Date:  1991-02

Review 2.  The role of neutrophil-activating mediators in canine health and disease (with special reference to the role of leukotrienes in inflammatory dermatoses).

Authors:  M Krogsgaard Thomsen
Journal:  J Vet Pharmacol Ther       Date:  1991-06       Impact factor: 1.786

3.  Effect of a 5-lipoxygenase (5-LO)/cyclooxygenase (CO) inhibitor, WY-47, 288, on cutaneous models of inflammation.

Authors:  R P Carlson; L O'Neill-Davis; W Calhoun; L Datko; J H Musser; A F Kreft; J Y Chang
Journal:  Agents Actions       Date:  1989-03

4.  Mouse skin inflammation induced by multiple topical applications of 12-O-tetradecanoylphorbol-13-acetate.

Authors:  P L Stanley; S Steiner; M Havens; K M Tramposch
Journal:  Skin Pharmacol       Date:  1991
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.